Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell ...

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with ...

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

Adding nivolumab to adjuvant CRT improved DFS in patients with locally advanced head and neck squamous cell carcinoma at high risk of relapse.

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

Adjuvant and neoadjuvant radiotherapy in bladder cancer treatment end results were not satisfactory during the last 3–4 decades, mainly owing to improper selection of patients and owing to the ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule ...

Adjuvant therapies are additional treatments, such as chemotherapy or radiation therapy, that help kill remaining cancer cells after primary therapy, like surgery, is complete. Treating breast ...

More information: PORTEC-4a; an international randomised trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer, Radiotherapy and Oncology (2025).

“Tamoxifen, radiation, or both, as well as the omission of any adjuvant therapy, are all reasonable options,” she said. “Now, we have more data to help our patients choose among these.

10-year all-cause survival. ‡ 48% of patients received neoadjuvant or adjuvant radiotherapy and/or chemotherapy. § 24% of patients received postoperative radiotherapy. LN+: Lymph nodal ...